Continuum has advised NVM Private Equity (NVM) on its £7 million investment into Chemigraphic, the leading provider of Electronic Manufacturing Services (EMS) to the fast-growth medical technology, defence and power systems sectors.
Chemigraphic, which has its headquarters in Crawley, builds complex products for a wide range of specialist UK and global technology brands, from conception to production, supporting them at every stage of their product lifecycle.
The investment, from NVM’s Vintage III fund, will help to accelerate Chemigraphic’s international growth and drive continued development of its technology and expertise, particularly in the fast-growing med-tech sector.
Continuum Director Steve Wycherley led the team advising on the deal from the Management Due Diligence perspective.
Steve said: “We’ve established a very strong relationship with NVM Private Equity and we’re pleased to have acted for the company on its exciting investment into Chemigraphic.”
NVM is independently owned with more than 30 years’ experience of investing in unquoted UK businesses and manages approximately £430 million of funds.
Peter Hodson and David Rolfe led the investment for NVM and Peter joined the Chemigraphic board upon completion.
Peter, Investment Partner of NVM Private Equity, said: “We are very excited to have the opportunity to work with Chris Wooton (CEO) and his team at Chemigraphic. The business has generated a lot of momentum since Chris joined the company two years ago benefiting from his laser focus on operational excellence and proactive business development. Chemigraphic’s current customer base is highly committed to the company, having benefitted from market leading service levels and product expertise. We are delighted to be coming on board at this exciting stage in the company’s development.”
